Company: CORT
Filing Date: 2025-07-31
Form Type: 10-Q
Source: 0001628280-25-037005
Chunk: 3

Company: CORCEPT THERAPEUTICS INC
Filing Date: 2025-07-31
Form: 10-Q
Item: Part I, Item 1
Chunk 3
---
2,693)Net effect of exchange rate changes on cash and cash equivalents1,794 (6)Net decrease in cash and cash equivalents(24,920)(6,963)Cash and cash equivalents, at beginning of period127,665 135,551 Cash and cash equivalents, at end of period$102,745 $128,588 

6

Supplemental disclosure: Exercise cost of shares repurchased for net settlement of cashless option exercises$12,056 $6,131 

The accompanying notes are an integral part of these condensed consolidated financial statements.

7

CORCEPT THERAPEUTICS INCORPORATED

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(Unaudited)

(In thousands)

Common StockAdditionalPaid-inCapitalTreasury StockAccumulated Other Comprehensive (Loss) IncomeRetained EarningsTotalStockholders’EquitySharesAmountBalance at December 31, 2024105,113 $136 $832,108 $(696,173)$(217)$543,735 $679,589 Issuance of common stock under incentive award plan1,712 1 12,899 — — — 12,900 Shares tendered to satisfy cost and statutory withholding requirements for net settlement of cashless option exercises and vesting of restricted stock(341)— — (21,086)— — (21,086)Repurchase of common stock in connection with Stock Repurchase Program(500)— — (27,433)— — (27,433)Stock-based compensation— — 15,687 — — — 15,687 Vesting of RSAs in connection with ESPP— — 2,172 — — — 2,172 Other comprehensive gain, net of tax— — — — 909 — 909 Net income— — — — — 20,547 20,547 Balance at March 31, 2025105,984 $137 $862,866 $(744,692)$692 $564,282 $683,285 Issuance of common stock under incentive award plan1,048 1 15,122 — — — 15,123 Shares tendered to satisfy cost and statutory withholding requirements for net settlement of cashless option exercises and vesting